Partner Publications

AfA Health Professional Newsletter

Aid for AIDS (AfA) was launched in May 1998 as a private sector HIV Disease Management programme providing a focused range of clinical interventions coupled with credible clinical support and on-going adherence management and patient support. The aim of the programme was to partner with healthcare providers and healthcare funders to optimize clinical outcomes by ensuring access to effective therapy and regular monitoring of outcomes and potential toxicity, thus limiting the frequency of treatment failure due to poor adherence or adverse effects. Sustained viral load suppression and immune recovery would reduce the risk of opportunistic infections and lead to improved survival. The programme has been successful and over 100,000 patients are currently receiving antiretroviral therapy with excellent clinical outcomes.

The AfA Clinical team can be contacted on 0800 227 700 or by email at Further information about AfA, the current treatment guidelines and back-copies of the quarterly newsletters can be found on the AfA website.


TB South

Published by i-base, a London-based treatment activist organisation, the HIV Treatment Bulletin is a not-for-profit community journal that reviews the most important advances in the clinical management of HIV and access to treatment. HTB-South is focused on Southern Africa and disseminated through SAHCS.


Issue 51

  • 31 Jul 2020

Update on Dolutegravir for children; Isoniazid preventive therapy in pregnancy: update

Issue 50

  • 31 Oct 2019

The importance of the gut microbiota to health in HIV; Update on risk for neural tube disorders for women on dolutegravir at conception: downgraded but real risk; No clinically significant interaction between dolutegravir and valproate

Issue 49

  • 29 Mar 2019

Tuberculosis Preventive Therapy for Adults; Undetectable = Untransmittable (U=U); Important drug-drug interactions with dolutegravir

Issue 48

  • 31 Jul 2018

Potential safety issue affecting HIV+ women taking dolutegravir at the time of conception; New WHO guidelines for induction therapy in cryptococcal meningitis; Treatment of cytomegalovirus (CMV) retinitis; Isoniazid preventive therapy (IPT) in pregnancy

Issue 47

  • 28 Feb 2018

Dolutegravir in pregnancy; Is there still a role for nevirapine?; The Xpert MTB/RIF Ultra: increased sensitivity for diagnosing HIV-associated TB with a small increase in false positive results; Treatment of multi-drug resistant gonorrhoea - what's in the pipeline?

Issue 46

  • 30 Sep 2017

Severe efavirenz-induced ataxia and encephalopathy; Prolonged post-treatment virologic control in a South African HIV+ child after early antiretroviral therapy; The DAWNING trial.

Issue 45

  • 01 Mar 2017

Early ART initiation as a factor in combating antibiotic resistance; Dolutegravir: not as monotherapy; BREATHER - Can HIV+ youth safely have a weekend off their antiretroviral medication?; Diagnosing "elite controllers"

Issue 44

  • 01 Oct 2016

Rifabutin dosing with protease inhibitors; Drug-drug interactions involving second generation NNRTIs; Pure Red Cell Aplasia in HIV

Issue 43

  • 01 Jun 2016

Dolutegravir: its use in adult patients Dolutegravir: its use in paediatric patients Drug-drug interactions between antiretrovirals and itraconazole Zika and HIV

Issue 42

  • 01 Feb 2016

Do elite controllers need ART? Early infant diagnosis of HIV - shifting paradigms Lifelong ART should be offered to ALL HIV-infected patients regardless of CD4 count Pneumococcal vaccination in HIV-infected persons

Issue 41

  • 01 Sep 2015

Probiotics and HIV Improved treatment outcomes in patients with XDR TB in South Africa HIV tests in children on ART Management of hyperlipidaemia in patients on protease inhibitors Cross-reactivity between darunavir and co-trimoxazole New 0199 tariff claiming process

Issue 40

  • 01 Jul 2015

Rilpivirine (RPV) in pregnancy Is there a need for 6-monthly CD4 monitoring in patients with stable virological suppression on ART? Twitter for the busy Clinician - Opening up a world of HIV-related information The role of micronutrient supplementation in adults

Issue 39

  • 01 Mar 2015

HIV-positive-to-HIV-positive renal transplantation Pre-exposure prophylaxis (PrEP): recent findings add to the evidence that it is effective as an HIV prevention tool Use of raltegravir in children Balancing risks and benefits in post exposure prophylaxis

Issue 38

  • 01 Nov 2014

Abacavir-based regimens in patients with high viral loads Proton pump inhibitor, H2 receptor blocker and antacid drug interactions with atazanavir/ritonavir Update on the Mississippi child - a reality check Maraviroc A festive reflection

Issue 37

  • 01 Aug 2014

The EARNEST trial: new evidence regarding efficacy of second line ART regimens New drug profile: rilpivirine The value of a psychological report in treatment failure Clinical Case Report - 35 year old male patient on a PMB Medical Scheme Option (Subject to State Protocols)

Vol 23 no 7

  • 01 Jul 2022

Monkeypox crisis UK; Conference reports; ARVs, Paediatric care

Vol 23 no 6

  • 06 Jun 2022

This issue of HTB includes several articles on different aspects of the current monkeypox (MPX) outbreak.

Vol 23 no 5

  • 02 May 2022

Conference reports; ARVs; Complications: Covid-19; HIV prevention

Vol 23 no 4

  • 01 Apr 2022

Donating meds to Ukraine and further reports from CROI 2022

Vol 23 no 3

  • 02 Mar 2022

Ukraine invaded, links to donate, 17 CROI 2022 reports…

Vol 22, no 7

  • 01 Jul 2021

New on new HIV and COVID drugs – and need for third vaccines…

Vol 22, no 6

  • 01 Jun 2021

Weight gain and weight loss, BHIVA, COVID-19 and vaccine efficacy at low CD4 counts…

Introduction to ART

  • 13 Oct 2016

This booklet is a guide for anyone interested in HIV treatment. It is especially for HIV positive people to feel more in control of this part of life. The guide was written and reviewed by HIV positive people, activists and health professionals. Information is based on the 2016 update to the UK guidelines and the pill chart include all newly approved drugs.

The 2014 Pipeline Report

  • 22 Jul 2014

The 2014 Pipeline report, co-authored by i-base and TAG, covers HIV, HCV and TB drugs, diagnostics, vaccines, preventive technologies, research toward a cure and immune-based and gene therapies in development

2013 Pipeline Report

  • 03 Jul 2013

The 2013 Pipeline report, co-authored by HIV i-base and TAG, covers HIV, HCV and TB drugs, diagnostics, vaccines, preventive technologies, research toward a cure and immune-based and gene therapies in development

Vol 5 No 1

  • 18 Apr 2012

HTB South: Conference coverage includes a meeting on HIV and women’s health, another on HIV persistence and cure research, as well as the European AIDS Conference and ICAAC.

Vol 4 No 4

  • 01 Dec 2011

HTB South: Includes final reports from IAS 2011 looking at the latest in cure research, ART and TB, and reassuring circumcision results from Orange Farm that dispel concerns about risk compensation.

July - Sept 2011

  • 01 Sep 2011

HTB South: This issue leads with the most important and exciting research from the IAS conference in Rome and the 3rd International Workshop on HIV Pediatrics immediately preceding it.

April - June 2010

  • 01 Apr 2010

HTB South: 16th Conference on Retroviruses and Opportunistic Infections

January - March 2010

  • 01 Jan 2010

HTB South: 17th Conference on Retroviruses and Opportunistic Infections (CROI)

October - December 2009

  • 01 Oct 2009

HTB South: 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV (IWADR)

April - June 2009

  • 01 Apr 2009

HTB South: 16th Conference on Retroviruses and Opportunistic Infections (CROI)

January - March 2009

  • 01 Jan 2009

HTB South: 16th Conference on Retroviruses and Opportunistic Infections

September - December 2008

  • 01 Sep 2008

HTB South: OCTANE Trial DSMB finds ritonavirboosted lopinavir superior to nevirapine in HIV-positive women previously exposed to single dose nevirapine

January - August 2008

  • 01 Jan 2008

HTB South: 38th World Conference on Lung Health of the Union against TB and Lung Disease